Menu Search
Equities

Numinus Wellness Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
LR23:STU

Numinus Wellness Inc

Actions
  • Price (EUR)0.025
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change--
  • Beta2.8045
Data delayed at least 15 minutes, as of Jan 30 2025.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Numinus Wellness Inc. is a mental healthcare company. It focuses on advancing traditional and behavioral health treatments, including safe, evidence-based psychedelic-assisted therapies. Its segments include Clinical research operations, Practitioner Training, Clinic network, and Corporate. Clinical research operations segment is focused on licensed psychedelic research and provides clinical research management services to academic institutions and biotechnology companies. Practitioner Training develops tailored education and training for research and drug development organizations to support clinical trials and commercialization efforts. Clinic network includes wellness clinics, which is engaged in providing clinical services from psychedelic-assisted therapies, transcranial magnetic stimulation, and psychiatric and medical model management. It is the integration of psychedelic-assisted therapies into mainstream clinical practice and building the foundation for a healthier society.

  • Revenue in CAD (TTM)5.33m
  • Net income in CAD-10.67m
  • Incorporated1962
  • Employees35.00
  • Location
    Numinus Wellness Inc393 Laurier Ave WMONTREAL H2V 2K3CanadaCAN
  • Phone+1 (604) 329-2079
  • Fax+1 (604) 329-2079
  • Websitehttps://numinus.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.